表紙
市場調查報告書

Alprazolam的全球市場:2020年∼2024年

Alprazolam Market by Type and Geography - Forecast and Analysis 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 918560
出版日期 內容資訊 英文 159 Pages
訂單完成後即時交付
價格
Back to Top
Alprazolam的全球市場:2020年∼2024年 Alprazolam Market by Type and Geography - Forecast and Analysis 2020-2024
出版日期: 2019年11月26日內容資訊: 英文 159 Pages
簡介

全球Alprazolam市場上,Alprazolam使用伴隨的藥物成癮增加,焦慮症及恐慌症的盛行率增加,藥物的低成本等成為成長促進因素,在預測期間內預計將以4%以上的年複合成長率擴大。可是,焦慮症和恐慌症相關的嚴格法規政策,有害的有副作用,社會的歧視眼光等要素,可能妨礙在預測期間內的Alprazolam產業的成長。

本報告提供全球Alprazolam市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 親市場
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2019年)
  • 市場規模及預測(2019年∼2024年)
  • 市場預測

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各類型

  • 市場區隔:各類型
  • 各類型比較:市場規模及預測(2019年∼2024年)
  • 焦慮症
  • 恐慌症
  • 其他
  • 市場機會:各類型

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2019年∼2024年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 藥物的再處方
  • 在新的研究領域的Alprazolam的使用
  • 容易成為焦慮症的老年人口的增加

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Amneal Pharmaceuticals Inc.
  • Cadila Healthcare Ltd.
  • Endo International Plc
  • Jazz Pharmaceuticals Plc
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR40207

About this market

Technavio's alprazolam market analysis considers sales of alprazolam in Asia, Europe, North America, and ROW. In 2019, the anxiety segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the rising number of campaigns to raise awareness about anxiety will play a significant role in the anxiety segment to maintain its market position. Also, our global alprazolam market report looks at factors such as increased drug dependency associated with the use of alprazolam, increasing prevalence of anxiety and panic disorders, and low cost of drugs. However, stringent regulatory policies, adverse side effects, and social stigma associated with anxiety and panic disorders may hamper the growth of the alprazolam industry over the forecast period.

Overview

Increasing prevalence of anxiety and panic disorders

The global alprazolam market is expected to benefit significantly from the strong prevalence of psychiatric indications such as anxiety and panic disorders. The increasing number of campaigns focusing on raising awareness about the severity of anxiety and panic disorders is expected to boost the demand for drugs for the treatment of such indications The prevalence of anxiety and panic disorders is also on the rise in the younger population due to changing lifestyles and increasing stress. As per a study conducted by the NIHI(National Institute of Health), panic disorders are prevalent in approximately 2.9% of the adult population in the US, with the prevalence rate being significantly higher in women than in men. Such factors will lead to the expansion of the global alprazolam market at a CAGR of over 4% during the forecast period.

Use of alprazolam in new research areas

The use of alprazolam was strictly limited to treat anxiety and panic disorders. However, with the growing demand for novel therapeutics for various indications, the research on alprazolam as a potential treatment option for other indications is increasing. Clinical-stage pharmaceutical vendors are collaborating to research alprazolam for the treatment of epilepsy. These vendors are focusing on developing Staccato Alprazolam as a Rapid Epileptic Seizure Termination (REST) therapy for providing relief from acute repetitive seizures. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global alprazolam market during the forecast period 2020-2024, view our report.

Competitive Landscape

With the presence of several major players, the global alprazolam market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading alprazolam manufacturers, that include Amneal Pharmaceuticals Inc., Cadila Healthcare Ltd., Endo International Plc, Jazz Pharmaceuticals Plc, Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and UCB SA.

Also, the alprazolam market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Parent market
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market outlook

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Anxiety - Market size and forecast 2019-2024
  • Panic disorders - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Drug reformulations
  • Use of alprazolam in new research areas
  • Increasing geriatric population prone to anxiety

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amneal Pharmaceuticals Inc.
  • Cadila Healthcare Ltd.
  • Endo International Plc
  • Jazz Pharmaceuticals Plc
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Vendors: Key product offerings
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2019
  • Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 10: Five forces analysis 2019
  • Exhibit 11: Five forces analysis 2024
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2019
  • Exhibit 18: Type - Market share 2019-2024 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Anxiety - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 21: Anxiety - Year-over-year growth 2020-2024 (%)
  • Exhibit 22: Panic disorders - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 23: Panic disorders - Year-over-year growth 2020-2024 (%)
  • Exhibit 24: Others - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 25: Others - Year-over-year growth 2020-2024 (%)
  • Exhibit 26: Market opportunity by type
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2019-2024 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 31: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 32: Top 3 countries in North America
  • Exhibit 33: Europe - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 35: Top 3 countries in Europe
  • Exhibit 36: Asia - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 37: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 38: Top 3 countries in Asia
  • Exhibit 39: ROW - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 40: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 41: Top 3 countries in ROW
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: Growth of geriatric population 2009-2018 (%)
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: Amneal Pharmaceuticals Inc. - Vendor overview
  • Exhibit 52: Amneal Pharmaceuticals Inc. - Business segments
  • Exhibit 53: Amneal Pharmaceuticals Inc. - Organizational developments
  • Exhibit 54: Amneal Pharmaceuticals Inc. - Segment focus
  • Exhibit 55: Amneal Pharmaceuticals Inc. - Key offerings
  • Exhibit 56: Amneal Pharmaceuticals Inc. - Key customers
  • Exhibit 57: Cadila Healthcare Ltd. - Vendor overview
  • Exhibit 58: Cadila Healthcare Ltd. - Business segments
  • Exhibit 59: Cadila Healthcare Ltd. - Organizational developments
  • Exhibit 60: Cadila Healthcare Ltd. - Geographic focus
  • Exhibit 61: Cadila Healthcare Ltd. - Key offerings
  • Exhibit 62: Cadila Healthcare Ltd. - Key customers
  • Exhibit 63: Endo International Plc - Vendor overview
  • Exhibit 64: Endo International Plc - Business segments
  • Exhibit 65: Endo International Plc - Organizational developments
  • Exhibit 66: Endo International Plc - Geographic focus
  • Exhibit 67: Endo International Plc - Segment focus
  • Exhibit 68: Endo International Plc - Key offerings
  • Exhibit 69: Endo International Plc - Key customers
  • Exhibit 70: Jazz Pharmaceuticals Plc - Vendor overview
  • Exhibit 71: Jazz Pharmaceuticals Plc - Business segments
  • Exhibit 72: Jazz Pharmaceuticals Plc - Organizational developments
  • Exhibit 73: Jazz Pharmaceuticals Plc - Geographic focus
  • Exhibit 74: Jazz Pharmaceuticals Plc - Key offerings
  • Exhibit 75: Jazz Pharmaceuticals Plc - Key customers
  • Exhibit 76: Mylan NV - Vendor overview
  • Exhibit 77: Mylan NV - Product segments
  • Exhibit 78: Mylan NV - Organizational developments
  • Exhibit 79: Mylan NV - Geographic focus
  • Exhibit 80: Mylan NV - Segment focus
  • Exhibit 81: Mylan NV - Key offerings
  • Exhibit 82: Mylan NV - Key customers
  • Exhibit 83: Novartis AG - Vendor overview
  • Exhibit 84: Novartis AG - Business segments
  • Exhibit 85: Novartis AG - Organizational developments
  • Exhibit 86: Novartis AG - Geographic focus
  • Exhibit 87: Novartis AG - Segment focus
  • Exhibit 88: Novartis AG - Key offerings
  • Exhibit 89: Novartis AG - Key customers
  • Exhibit 90: Pfizer Inc. - Vendor overview
  • Exhibit 91: Pfizer Inc. - Business segments
  • Exhibit 92: Pfizer Inc. - Organizational developments
  • Exhibit 93: Pfizer Inc. - Geographic focus
  • Exhibit 94: Pfizer Inc. - Segment focus
  • Exhibit 95: Pfizer Inc. - Key offerings
  • Exhibit 96: Pfizer Inc. - Key customers
  • Exhibit 97: Sun Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 98: Sun Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 99: Sun Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 100: Sun Pharmaceutical Industries Ltd. - Geographic focus
  • Exhibit 101: Sun Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 102: Sun Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 103: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 104: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 105: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 106: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 107: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 108: Teva Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 109: UCB SA - Vendor overview
  • Exhibit 110: UCB SA - Business segments
  • Exhibit 111: UCB SA - Organizational developments
  • Exhibit 112: UCB SA - Geographic focus
  • Exhibit 113: UCB SA - Key offerings
  • Exhibit 114: UCB SA - Key customers
  • Exhibit 115: Validation techniques employed for market sizing
  • Exhibit 116: Definition of market positioning of vendors
Back to Top